MedTrace Logo

Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma

NCT03349255 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2019-07-01

No results posted yet for this study

Summary

Clinical study to evaluate safety and pharmacokinetics (primary objectives) and efficacy (secondary objective) of ET1402L1-CART-cells in patients with AFP+ HCC

Conditions

Interventions

BIOLOGICAL

autologous ET1402L1-CART cells

Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1)-CAR expression construct

Sponsors & Collaborators

  • Renmin Hospital of Wuhan University

    collaborator OTHER

  • Eureka Therapeutics Inc.

    collaborator INDUSTRY

  • Aeon Therapeutics (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Qibin Song, M.D./Ph.D. · Renmin Hospital of Wuhan University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-06
Primary Completion
2019-01-10
Completion
2019-01-10
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03349255 on ClinicalTrials.gov